Genetic Polymorphisms of @entity4654 and @entity15588 Could Be Predictive Factors of the Long-Term Effect of Infliximab against XXXX .

@entity1 @entity72483 @entity72482 @entity4654 @entity15588 @entity30
UNASSIGNED: Background. We aimed to identify certain genes related to response to infliximab (IFX) and biomarkers to predict the IFX effect for Japanese @entity30 ( @entity30 ) @entity1 by performing an association study of single nucleotide polymorphisms (SNPs) in candidate genes in the interleukin- (IL-) 17 signaling pathway with response to IFX after 1 year of treatment. Methods. A total of 103 @entity1 were divided into two groups, responders and nonresponders. Twenty-eight tag SNPs in 5 genes were genotyped. The frequencies of alleles and genotypes of each SNP were compared between responders and nonresponders in three different inheritance models. A genetic test was performed using a combination of the associated SNPs as biomarkers. Results. Multivariate logistic regression analysis indicated that the four variable factors, concomitant use of immunomodulators, penetrating disease, a G/G genotype of @entity72482 in @entity4654 , and a C/C or C/A genotype of @entity72483 in @entity15588 , independently contributed to response to IFX after 1 year of treatment. Genetic test using the polymorphisms of these genes perfectly predicted the responder and nonresponder @entity30 @entity1 with both concomitant use of immunomodulators and penetrating disease. Conclusion. @entity4654 and @entity15588 are one of IFX-related genes, useful as biomarkers of IFX response, and may be target molecules for new therapeutic drugs.
